These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Management of patients infected by the human immunodeficiency virus (HIV). Report of an expert group]. Delfraissy JF; Rev Pneumol Clin; 2002 Dec; 58(6 Pt 1):312-40. PubMed ID: 12545131 [No Abstract] [Full Text] [Related]
5. Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection. Li JC; Yim HC; Lau AS AIDS; 2010 Jul; 24(11):1609-23. PubMed ID: 20588103 [No Abstract] [Full Text] [Related]
7. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy. Green H; Hay P; Dunn DT; McCormack S; HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617 [TBL] [Abstract][Full Text] [Related]
8. [Prevention of wasting and opportunistic infections in HIV-infected patients in West Africa: a realistic and necessary strategy before antiretroviral treatment]. Ledru é ; Sanou PT; Dembele M; Dahourou H; Zoubga A; Durand G Sante; 1999; 9(5):293-300. PubMed ID: 10657773 [TBL] [Abstract][Full Text] [Related]
9. [Treatment of AIDS and associated diseases]. Rytik PG Klin Med (Mosk); 1997; 75(1):5-10. PubMed ID: 9082063 [No Abstract] [Full Text] [Related]
10. [Antiretroviral therapy 1994 versus 2004. The reality illustrated by typical cases]. Kuhlmann B; Trein A MMW Fortschr Med; 2004 Apr; 146 Spec No 1():72-3. PubMed ID: 15373057 [No Abstract] [Full Text] [Related]
11. HIV/AIDS. Malawi: a suitable case for treatment. Cohen J Science; 2002 Aug; 297(5583):927-9. PubMed ID: 12169711 [No Abstract] [Full Text] [Related]
12. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Guex AC; Radziwill AJ; Bucher HC Clin Infect Dis; 2000 Mar; 30(3):602-3. PubMed ID: 10722454 [No Abstract] [Full Text] [Related]
13. [HIV/AIDS treatment. Many attenuating drugs but still no remedy]. Sandström E Vardfacket; 1993 Jun; 17(10):V-IX. PubMed ID: 8109133 [No Abstract] [Full Text] [Related]
14. Reconstitution of immunity against opportunistic infections in the era of potent antiretroviral therapy. Aberg JA AIDS Clin Rev; 2000-2001; ():115-38. PubMed ID: 10999219 [TBL] [Abstract][Full Text] [Related]
15. Alternative approach to AIDS defense shows promise. Marino D Dent Today; 1997 Jan; 16(1):28, 31. PubMed ID: 9560623 [No Abstract] [Full Text] [Related]
16. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy. Jubault V; Pacanowski J; Rabian C; Viard JP Ann Med Interne (Paris); 2000 May; 151(3):163-8. PubMed ID: 10896967 [TBL] [Abstract][Full Text] [Related]
17. Some relief from the epidemic. Cadman JA GMHC Treat Issues; 1997 Mar; 11(3):1-3. PubMed ID: 11364274 [TBL] [Abstract][Full Text] [Related]
19. The value of preserving HIV-specific immune responses. Kaufmann DE; Rosenberg ES J HIV Ther; 2003 Feb; 8(1):19-25. PubMed ID: 12840711 [TBL] [Abstract][Full Text] [Related]
20. Preaching what we practice: new guidelines for OI prophylaxis. Feinberg J AIDS Clin Care; 1999 Nov; 11(11):87-9, 94. PubMed ID: 11366709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]